A Single Center,Real World Experience to Determine the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir (3D regimen) With or Without Ribavirin for Treating Hepatitis C Virus Genotype 1 Infection in Patients With and Without Cirrhosis.

Trial Profile

A Single Center,Real World Experience to Determine the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir (3D regimen) With or Without Ribavirin for Treating Hepatitis C Virus Genotype 1 Infection in Patients With and Without Cirrhosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2016 New trial record
    • 24 May 2016 Results (n=76) presented at the Digestive Disease Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top